Thrombosis refers to formation of blood clots within blood vessels, which can obstruct blood flow and cause major complications such as pulmonary embolism, stroke, or organ ischemia. Venous thromboembolism is a major preventable cause of morbidity and mortality.
Grifols has launched FESILTY (fibrinogen, human-chmt) in the U.S., a fibrinogen concentrate FDA-approved in December 2025 for acute bleeding episodes in patients with congenital fibrinogen deficiency. The highly purified product, developed by Biotest, enables rapid fibrinogen restoration and can be reconstituted in approximately three minutes.
The U.S. cardiovascular drugs market is projected to reach $37.03 billion by 2035, growing at a CAGR of 2.68%. Europe's anticoagulants market is expected to reach $23.68 billion by 2033, expanding at a CAGR of 8.22%.
ADARx will present onvuzosiran Phase 1/2 data and Phase 3 STOP-HAE design at AAAAI and EAACI 2026. The investigational siRNA for hereditary angioedema has FDA Orphan Drug Designation.
The European Commission expanded Hympavzi approval to patients 12 and older with hemophilia A or B with inhibitors. Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy.
The FDA has issued draft guidance that may speed approval pathways for rare disease therapies using genome editing technologies, potentially benefiting CRISPR Therapeutics' pipeline of six clinical-stage candidates.
Switzerland-based CRISPR Therapeutics stands to benefit from increased Casgevy sales following partner Vertex Pharmaceuticals' fourth-quarter results, with five additional gene-editing therapies in clinical trials targeting larger patient populations.
International researchers have identified a specific antibody mutation that causes rare but serious blood clots after adenovirus-based COVID-19 vaccines or natural adenovirus infection, providing a roadmap for safer vaccine design.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07644247 |
STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump |
NOT_YET_RECRUITING | PHASE4 |
| NCT07643246 |
National Study on the Prevalence of Catheter-Related Venous Thrombosis |
NOT_YET_RECRUITING | |
| NCT07632976 |
A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07618351 |
A Phase I SAD/MAD and Liver Effect Study of Vitalangio in Venous Thromboembolism Patients . |
COMPLETED | PHASE1 |
| NCT07613840 |
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease |
RECRUITING | NA |
| NCT07597239 |
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization |
ACTIVE_NOT_RECRUITING | NA |
| NCT07580469 |
Platelets and Extracorporeal Membrane Oxygenation Veno-venous |
NOT_YET_RECRUITING | |
| NCT07523880 |
Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD |
RECRUITING | |
| NCT07519304 |
Effectiveness of a Needle-free Connector With Anti-reflux Technology in Reducing Complications From Long Peripheral Venous Catheters in Hospitalised Adult Patients: Randomised Clinical Trial |
NOT_YET_RECRUITING | NA |
| NCT07498517 |
Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT |
NOT_YET_RECRUITING | PHASE2 |
